Android app Apple app link

Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

By Yahoo! Finance   |   1 month ago
Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients

Stifel analysts reiterated a Buy rating and $48 price target for Bicara Therapeutics Inc. after ASCO abstract release. Positive results for HPV-negative patients, but caution advised due to competing data from Merus.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.